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Abstract
Background: It is not known whether a 400 μg dose of misoprostol has a similar efficacy as an
800 μg dose when administered sublingually or vaginally 24 hours after 200 mg mifepristone.
Methods: It is proposed to undertake a placebo-controlled, randomized, non-inferiority trial (3%
margin of equivalence) of the two misoprostol doses when administered sublingually or vaginally
using factorial design. A total of 3008 pregnant women (< 63 days of gestational age) who request
legal termination of pregnancy will be recruited for the trial at 16 clinics in ten countries providing
abortion services. Eligible women willing to join the study will be allocated randomly to one of the
four treatment groups within each centre. Women in all treatment groups will first receive 200 mg
mifepristone, followed 24 hours later by either 400 μg or 800 μg misoprostol, administered either
sublingually or vaginally. The dose and route of administration of misoprostol will be blinded to
women, each woman receiving four tablets vaginally and four tablets sublingually, two or four of
which are 200 μg tablets of misoprostol and the rest are placebo tablets.
The four treatment regimens will be compared in terms of: (i) their efficacy to induce complete
abortion; (ii) induction-to-abortion interval when possible; (iii) the frequency of side effects; and
(iv) women's perceptions. The initial judgment of the outcome of treatment is made at the follow-
up visit on day 15 of the study and the final assessment four weeks later. It is estimated that the
clinical phase will require 12–14 months for data collection.
To compare the two routes and two doses, relative risks (RR) of failure to achieve a complete
abortion and failure to terminate pregnancy and the two-sided 95% CIs will be calculated by
standard methods, as well as risk differences and two-sided 95% CIs. The latter will be used to test
the non-inferiority hypotheses (at 2.5% level of significance) for achieving complete abortion. The
factorial structure will be taken into account in the analysis after testing the interaction.
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Background
The approved regimen for medical abortion in most coun-
tries is 600 mg mifepristone followed 36–48 hours later
by 400 μg misoprostol orally up to 49 days of gestation.
Between 50 and 63 days, 1 mg gemeprost or 800 μg mg
misoprostol administered vaginally is used instead. The
data of several multicentre trials conducted over the past
ten years demonstrate that for the termination of early
pregnancy a single dose of 200 mg of mifepristone is as
effective as 600 mg [1-3]. Thus, in the guidelines on safe
abortion (Safe Abortion: Technical and Policy Guidance
for Health Systems WHO 2003) the recommended regi-
men is 200 mg mifepristone followed by misoprostol,
400 μg orally (≤ 49 days) or 800 μg vaginally (≤ 63 days).
When misoprostol is administered orally, the dose of 400
μg is used, while 800 μg is administered vaginally. There
is no rationale, however, for the use of a higher vaginal
dose, because according to pharmacokinetics data and
results from studies on uterine contractility, vaginal route
should be more effective: compared to oral administra-
tion, plasma concentration after vaginal administration
stays high for longer [4,5] and the effect on uterine con-
tractility follows the same pattern [6]. There are no studies
comparing vaginal doses of 400 μg and 800 μg of misopr-
ostol. Our hypothesis is that vaginal 400 μg will be suffi-
cient and that 800 μg dose is not needed. In fact, if the
lower dose has a similar efficacy, it would be unethical to
continue using a dose that is unnecessarily high because it
is likely to cause more side effects and increase the costs of
the treatment.
It has recently been demonstrated that sublingual admin-
istration of misoprostol might be an alternative to vaginal
treatment. Pharmacokinetic studies have shown that the
plasma levels of misoprostol were higher and the area
under the curve of misoprostol concentration versus time
up to 360 minutes was significantly greater than those fol-
lowing oral and vaginal administration [5]. After sublin-
gual administration the increase in uterine tonus is more
rapid and more pronounced than after vaginal adminis-
tration, but the contractions start to decrease after about 3
hours compared to 4–5 hours after vaginal dose [7,8]. In
a pilot study using misoprostol alone [9], a dose of 600 μg
was administered sublingually every 3 hours for a maxi-
mum of 5 doses to women requesting medical abortion at
up to 12 weeks gestation. The overall complete abortion
rate was 86%. Diarrhoea, fever and chills were the most
common side-effects. Almost all women who had a com-
plete abortion would have chosen this method again. The
sublingual route was regarded as convenient and gave
more privacy during the abortion process.
In a recent study undertaken in collaboration with our
Programme [10], 800 μg misoprostol was administered
either vaginally or sublingually after pretreatment with
mifepristone for termination of pregnancy. The study
included 224 women up to 63 days of gestation. Com-
plete abortion rates were 93.8% and 98.2% after vaginal
and sublingual administration, respectively, indicating
that the sublingual route could be superior to the vaginal.
However, the incidence of side-effects was higher after
sublingual administration. Another study also suggested a
very high efficacy after sublingual administration of 600
μg of misoprotol among 96 women treated, as 93 of them
(98.9%) had a complete abortion [11].
No previous studies have tested 400 μg dose of misopros-
tol, either sublingual or vaginal, in the first trimester. It
does not seems logical to administer a dose for vaginal use
that is twice as high as the dose recommended for oral use
when scientific data shows the vaginal route to be more
efficient. It seems also relevant to test the possibility that
sublingual administration might be at least as effective as
vaginal administration since a non-vaginal route of
administration is preferred by many women [9,12].
The results of our recent study [13] demonstrate an equiv-
alent efficacy for both 24 h and 48 h intervals when 800
μg misoprostol is administered vaginally after mifepris-
tone. As 24 h interval is more practical it is likely to
become the standard in mifepristone-misoprostol regi-
mens. This is why we chose the 24 h interval for the
present trial.
The ultimate goal of our research is to improve the meth-
ods for termination of early pregnancy. The main objec-
tive of the present randomized trial is to compare four
misoprostol regimens when administered either sublin-
gually or vaginally 24 hours after 200 mg of mifepristone,
among women with a gestational age of up to 63 days.
The four regimens will be compared in respect of the fol-
lowing main outcomes: (i) their efficacy to induce com-
plete abortion; (ii) induction-to-abortion interval, when
possible; (iii) the occurrence of side-effects; and (iv)
women's perceptions.
Although there are no comparative studies the efficacy
might be somewhat lower if the dose of misoprostol is
reduced. If, however, the side-effects will decrease and the
regimen is more acceptable to women, it would be justi-
fied to use a lower dose if non-inferiority is demonstrated
within a margin of 3%. Our hypothesis is that the efficacy
of 400 μg misoprostol, whether given sublingually or vag-
inally after mifepristone pretreatment, is not inferior to
that of 800 μg misoprostol within a margin of 3%.
Methods/design
The design of the study will be placebo-controlled, single-
blind, randomized, stratified by centre and by the lengthReproductive Health 2008, 5:2 http://www.reproductive-health-journal.com/content/5/1/2
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of gestation: <49 days; 50–56 days; 57–63 days. A total of
3008 women with pregnancies of < 63 days from last
menses (verified by ultrasound) will be recruited for the
study in participating centres (188 subjects per centre; 62–
64 per each strata of gestation) from among women
requesting legal termination of pregnancy and who prefer
medical abortion. All subjects will get 200 mg mifepris-
tone orally, and 24 (+/- 2) hours later they will receive
either: 4 placebo tablets vaginally and 2 tablets of misopr-
ostol and 2 placebo tablets sublingually; or 4 placebo tab-
lets vaginally and 4 tablets of 200 μg misoprostol
sublingually; or 2 tablets of 200 μg misoprostol plus 2 pla-
cebo tablets vaginally and 4 placebo tablets sublingually;
or 4 tablets of 200 μg misoprostol vaginally and 4 placebo
tablets sublingually.
The dose and route of administration of misoprostol will
be blinded to the women. Side-effects will be recorded at
hourly intervals up to 3 hours after misoprostol adminis-
tration. The preliminary outcome will be assessed before
the woman leaves the clinic. The final outcome regarding
the efficacy, side-effects since treatment and acceptability
will be assessed at the follow-up visits on Day 15 and Day
42 of the study unless women are still bleeding and
require a further follow-up.
This multinational trial will be carried out in 16 depart-
ments of obstetrics and gynaecology of teaching hospitals.
All departments provide routine abortion services and
also carry out clinical research. The trial will be conducted
according to ICH-GCP guidelines and the investigators are
trained to carry out research accordingly.
A total of 3008 women (188 women at each of the 16 par-
ticipating centres) will be recruited from among women
requesting legal termination of pregnancy during 12
months. Women admitted to the study will fulfil all of the
following criteria: good general health; older than the age
of legal consent; requesting abortion and eligible for legal
termination of pregnancy; on Day 1 of the study (day of
mifepristone administration) the duration of pregnancy
not more than 63 days, verified by ultrasound; the preg-
nancy is single and intrauterine (single sac); if treatment
with misoprostol should fail agrees to surgical termina-
tion of pregnancy; willing and able to participate after the
study has been explained; and haemoglobin higher than
90 g/l.
Any indication of serious past or present ill health will be
considered a contraindication for recruitment to the
study. In particular, women should not be recruited if any
of the following conditions is present: allergy towards
mifepristone or misoprostol; a history or evidence of dis-
orders that represent a contraindication to the use of mife-
pristone (chronic adrenal failure, severe asthma
uncontrolled by corticosteroid therapy, inherited porphy-
ria) or prostaglandins (mitral stenosis, sickle cell anaemia,
diastolic pressure over 90 mm Hg, systolic blood pressure
lower than 90 mm Hg measured with a traditional instru-
ment); a history or evidence of thrombo-embolism,
severe or recurrent liver disease; has a medical condition
or disease that requires special treatment, care or precau-
tion (e.g. corticosteroid or anticoagulant therapy) in con-
junction with abortion; uterine fibroids are relative
contraindication (women with fibroids that are likely to
affect bleeding or contractility should be excluded); the
presence of an IUD in utero; breastfeeding; previous sur-
gery of uterus/uterine cervix is a relative contraindication.
However, previous low-segment caesarean section does
not need to be a contra-indication; suspicion of any
pathology of pregnancy (e.g. molar, non-viable preg-
nancy, threatened abortion); in case difficulties are antic-
ipated in the follow-up of the woman (e.g. lives too far).
Women older than 35 years can be recruited for the
present trial provided they do not smoke, their diastolic
blood pressure is < 90 mmHg and have no known risk fac-
tors for cardiovascular disease.
The main efficacy analysis will include all women rand-
omized for whom outcome is known. Criteria for exclu-
sion from per-protocol analysis are the following:
essential data are missing from the participant's records
making it impossible to judge treatment outcome (same
as for main analysis); any violation of the study protocol,
including violation of eligibility criteria; and treatment
non-compliance.
At each of the participating centres, eligible women will be
allocated randomly using blocks of variable size to the
four treatment groups using computer-generated random
tables. These tables will be produced by the Programme's
Statistics and Informatics Services Team. Each participat-
ing woman will have two medicine packs: one for Day 1
of the study containing one tablet of 200 mg of mifepris-
tone; and the other for Day 2 of the study (24 hours later)
containing 4 tablets to be taken vaginally (either 4 pla-
cebo tablets in groups A and B, or 2 misoprostol and 2 pla-
cebo tablets in group C, or 4 misoprostol tablets in group
D); and 4 tablets to be taken sublingually (either 2 tablets
of misoprostol and two placebo tablets in group A; or 4
misoprostol tablets in group B; or 4 placebos in groups C
and D). The misoprostol tablets and placebo tablets will
be packed in blisters. On the blisters it is indicated which
tablets are taken vaginally and which tablets are taken
sublingually. All subjects will have the same number of
tablets administered vaginally and sublingually. We will
use mifepristone (Exelgyn) and misoprostol (Pfizer) tab-
lets which are available in many European countries.Reproductive Health 2008, 5:2 http://www.reproductive-health-journal.com/content/5/1/2
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Study procedures
Before admission to the study potential subjects will
undergo the following: ultrasound examination to verify
the length of the pregnancy and check that the pregnancy
is intrauterine. If the pregnancy is more advanced, if there
is a suspicion about an abnormal pregnancy (e.g. extrau-
terine, molar pregnancy, etc.) the woman will not be
admitted to the study; haemoglobin measurement; the
blood group and Rh typing according to the routine of the
centre; full medical, obstetrical and gynaecological his-
tory; full medical and gynaecological examination includ-
ing pelvic examination, height, weight and blood
pressure; and bacteriological examination according to
the routine of the centre.
Women who fulfil the criteria for admission and who are
willing and able to participate in the trial and have given
their informed consent will be included in the study.
Women admitted to the study will be given a diary card to
record days and amount of vaginal bleeding and side-
effects. The card will also give the dates of the follow-up
visits. The day of start of the treatment will constitute the
day of formal admission to the study (i.e. Day 1 of the
study) when the length of pregnancy should not be more
than 63 days. The tablet of mifepristone must be swal-
lowed in the presence of a member of the study team who
will record on the data form the date and time when the
tablet was taken.
All centres will have subject numbers from 1–192. As we
plan to take randomly 4 packs of tablets per centre for
quality control, each centre will recruit 188 women for the
study. To ensure an equal representation of women with
longer duration of pregnancy (beyond 49 days) at each
centre, subject numbers will be divided between each cat-
egory of gestational length so that the numbers 1–64 are
used for women with the duration of pregnancy up to 49
days, 65–128 for 50–56 days and 129–192 for pregnan-
cies of 57–63 days.
After the admission visit on Day 1 all subjects will attend
the clinic on three occasions during the course of the
study.
Day 2 visit: during this visit which 4 tablets of misoprostol
are administered vaginally and 4 tablets sublingually
(right after the vaginal dose the first two sublingual tab-
lets, and when they have melted/or after 20 minutes, the
additional two tablets sublingually) followed by a 3-hour
clinical observation period (hourly recordings of blood
pressure, pulse rate, possible side-effects and of any med-
ications given). Both the times of tablet administration
and of expulsion of products of conception, if it occurs,
will be recorded on the data forms. There will be a vaginal
examination at the end of the 3-hour observation period.
Day 15 visit is the first follow-up visit. During this visit a
medical interview will take place, the diary card is
reviewed and a physical and gynecological examination
will take place. A blood sample is taken to measure hae-
moglobin and ultrasound examination is done if judged
necessary from clinical findings.
Day 43 visit is the second follow-up visit during which the
same procedures are carried out as for Day 15, but Hb
measurement is not mandatory at this visit. If the woman
has not had a spontaneous menstruation by the time of
the second follow-up visit, she should have a further fol-
low-up appointment at a date to be decided by the inves-
tigator, or she can provide the information by telephone
if that is more convenient.
Assessment of the outcome of treatment
The primary outcome is the efficacy of the treatment in
achieving complete abortion and in terminating preg-
nancy. In addition, the four regimens will be compared in
respect of the following outcomes: induction-to-abortion
interval, when possible; the occurrence of side-effects; and
women's perceptions about the treatments.
Efficacy
The efficacy outcome of the treatment will be classified on
the basis of the subject's history and the clinical findings
at pelvic US examination, as 1) complete abortion –
uterus empty; 2) incomplete abortion – remnants of tis-
sue in uterus; 3) missed abortion – intrauterine sac with-
out heart beats; 4) failed termination of pregnancy – live
pregnancy, heart beats seen in US; 5) lost to follow, out-
come unknown; and 6) Other, including vacuum aspira-
tion on woman's request or when indicated medically
before outcome can be assessed.
Even if the woman aborts already after mifepristone,
before administration of misoprostol, she will be given
misoprostol. The initial judgment about the outcome of
therapy is made at the first follow-up visit (Day 15 of the
study). If the clinical findings at pelvic examination are
suggestive of a continuing pregnancy, an ultrasound
examination will be performed. In subjects with live preg-
nancy (i.e. fetal heart activity present) vacuum aspiration
will be performed. In case of missed abortion the investi-
gator may perform vacuum aspiration or continue to fol-
low-up according to the clinical situation.
If the clinical findings at the Day 15 visit are compatible
with incomplete abortion, no further action will be taken,
unless judged necessary by the investigator, e.g. because of
heavy vaginal bleeding or signs of pelvic infection. The
final judgment on the outcome of therapy is made at the
second follow-up visit on Day 43 of the study. If no emer-
gency or elective curettage was necessary during the periodReproductive Health 2008, 5:2 http://www.reproductive-health-journal.com/content/5/1/2
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up to the first menstruation, the outcome of treatment is
classified as "complete abortion". The remaining cases in
which curettage was done will be classified in the first
analysis as "incomplete abortion". If the women discon-
tinues the treatment and has vacuum aspiration before the
outcome is known, the outcome will be regarded as
"undetermined".
Induction-to-abortion interval
Induction- to-abortion interval is the time in hours from
the start of treatment (mifepristone administration on
Day 1) until the expulsion of the products of conception.
According to our previous experience up to 70% of the
expulsions take place in the clinic during the three-hour
observation period after misoprostol administration. The
time of expulsion will be recorded on the data collection
forms. If expulsion does not occur at the clinic, women are
asked to record the time in the daily record charts. It is
understood that in very early pregnancies it may not
always be possible to identify the time of expulsion.
Incidence of side-effects
Signs and symptoms will be recorded at admission, and
women will keep daily records of any complaints and
medication taken, for the duration of the whole trial and
report them at each visit. Data on signs and symptoms
will be collected prior to misoprostol administration and
immediately after administration as well as at one-hour
intervals up to three hours. In addition, the intensity of
side effects is recorded indicating whether side-effects
were mild, moderate or severe. However, the pain is
recorded using the scale from 0–10, in which 0 means no
pain and 10 is the worst possible pain the subject can
imagine.
We classify the signs and symptoms that women may have
during the trial as follows: Pregnancy-related symptoms:
such as nausea, vomiting, breast-tenderness, fatigue, diz-
ziness, headache and fainting; Drug-related side-effects,
such as diarrhoea, fever and rash; and side-effects related
to the abortion process, such as lower abdominal pain
and bleeding.
Women's perceptions
Women's perceptions on the treatments are assessed at the
first follow-up visit using slightly modified versions of the
questionnaires from our previous trials.
An individual subject's participation in the study is dis-
continued if she wants to withdraw her participation or is
lost to follow-up. Side-effects such as nausea, vomiting,
uterine pain, etc. that may occur in some women during
the course of the induced abortion do not constitute a rea-
son for discontinuation and will be treated symptomati-
cally where necessary.
An independent Data Monitoring Committee (DMC) will
be appointed to monitor the safety of the study. Its mem-
bers will discuss the results of interim analyses, will assess
whether the magnitude of the difference in the outcomes
and side-effects is clinically relevant and/or whether it is
associated with the treatment and will give recommenda-
tions to the trial Steering Committee regarding stopping
the trial prematurely. The ultimate decision about the
study discontinuation will be the responsibility of the trial
co-ordinator, who without delay will make the informa-
tion about such a decision available to the participating
centres. If any investigator is worried about any symptoms
related to the treatment (s)he has to inform the Pro-
gramme immediately.
The decision whether or not to discontinue a lower dose
regimen, because of low efficacy will be based on its com-
parison with the regimen of 200 mg mifepristone fol-
lowed by 800 μg misoprostol vaginally 24 hours later.
Two interim analyses will be conducted, respectively,
when data for 700 subjects are available for analysis in the
electronic data file and when data for 1300 subjects are
available, or at any point when DMC requests for it. The
significance level at the final analysis will be adjusted
using Haybittle-Peto rule.
Pre-admission tests and haemoglobin measurement
(Days 1 and 15) will be carried out by methods routinely
employed at each centre. Ultrasound examinations will be
done to verify the length of the pregnancy before admis-
sion and, if judged necessary from clinical findings, any
time during the study.
Data management
Participating centres will be requested to record the data
on paper data collection forms, enter them and send them
electronically on a weekly basis to Geneva, using a Web-
based system [14]. Recruitment and data quality will be
monitored by the Programme's Statistics and Informatics
Services Team using this system.
Data will be analyzed centrally in Geneva. Descriptive sta-
tistics will be calculated for all baseline characteristics for
all subjects randomized, by treatment group, to describe
characteristics of the population and to assess compara-
bility of the groups. The overall summary statistics for
women who complete the trial will be compared with
those for the subjects lost to follow-up.
All subjects randomized having known outcome will be
included in the main efficacy analysis in their randomized
groups. If attempts fail to locate and contact a woman lost
to follow-up, and her outcome of treatment is not known,
then that woman will be excluded from the efficacy anal-
ysis. If she has information on side effects, she will beReproductive Health 2008, 5:2 http://www.reproductive-health-journal.com/content/5/1/2
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included in the safety analysis. Baseline characteristics of
women lost to follow-up will be compared with those
completing the study and between groups, to explore the
possibility of bias due to these differences.
Crude rates for each outcome will be calculated in each
arm and exact confidence intervals based on the binomial
distribution calculated as described in Armitage and Berry
[15]. If the interaction of misoprostol route by misopros-
tol dose is significant at 5% level, comparisons will be
made between routes for each dose and between doses for
each route. If the interaction is not significant at 5%, two
comparisons will be made, between routes for the two
doses combined, and between doses for the two routes
combined. For these comparisons, relative risks (RR) of
failure to achieve a complete abortion and failure to ter-
minate pregnancy and the two-sided 95% CIs will be cal-
culated by standard methods, as well as risk differences
and two-sided 95% CIs. The latter will be used to test the
non-inferiority hypotheses (at 2.5% level of significance)
for achieving complete abortion.
Stratified analysis for efficacy will be conducted by gesta-
tional age (up to and including 49 days, 50–56 days and
57–63 days). Adjusted analysis by centre and for any prog-
nostic variable showing imbalance at baseline will be per-
formed using Mantel-Haenszel approach and/or logistic
regression where appropriate. A per-protocol analysis will
be performed excluding women with conditions as
described in earlier sections. Efficacy will also be calcu-
lated excluding subjects with undetermined outcome.
Survival analysis if appropriate will be used to compare
the differences in induction-abortion intervals. Chi-
square test or Fisher exact test as appropriate, will be used
to compare the proportion of women with each side-
effect, adjusting for multiple inferences with an appropri-
ate technique.
Number of subjects and statistical power
To establish the non-inferiority (one-sided equivalence)
of the 400 μg misoprostol (sublingual or vaginal) regimen
compared to the 800 μg with respect to efficacy, we
require the upper limit of the one-sided 95% confidence
interval (or the two-sided 95% confidence interval) for a
difference in complete abortion rates (that of 800 μg
minus that of 400 μg) to be within a margin of equiva-
lence of 3%. It is estimated that if the abortion rates in the
two regimens are both equal to 95%, about 680 subjects
will be required in each group to demonstrate non-inferi-
ority with a power of 80%, i.e. a total of about 2720 sub-
jects. To allow for a 5% of women lost to follow-up or
with undetermined outcomes, then about 720 women
will have to be recruited per group, a total of about 2880.
If 15 centres participate in the study, 192 subjects will be
needed in each centre. However, to ensure recruitment in
one year time, we plan to include one additional centre,
16 centres in all. Since we plan to take four packs per cen-
tre for quality control, the actual number of women
recruited per centre will be 188. These calculations allow
for the presence of an interaction between misoprostol
dose and its route of administration.
For the choice of the non-inferiority margin, a clinical cri-
terion was used, not a statistical one. This is based on the
fact that there are not placebo-controlled trials available
and the efficacy of placebo would be close to zero. We set
the margin at 3% based on clinical assessment that this
difference is not relevant.
It is estimated that the trial will require 12 to 14 months
for data collection at each centre and between 6 and 12
months of centralized data analysis in Geneva.
Project management
The trial will be conducted in 16 collaborating centres
under the supervision of a principal investigator in each
centre. The responsibilities of principal investigators are
described in the "Guidelines for Investigators" for this
project. Overall co-ordination of the project will be the
responsibility of the Manager and statistical staff of the
Programme's Group for Research on Post-ovulatory Meth-
ods for Fertility Regulation. This responsibility will
include, inter alia, the organization and supervision of the
trial, communication with the principal investigators, and
the analysis and writing-up of the results.
This trial will be funded by the Packard Foundation and
the UNDP/UNFPA/WHO/World Bank Special Pro-
gramme of Research, Development and Research Training
in Human Reproduction, Department of Reproductive
Health and Research, World Health Organization.
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